Experts reveal potential unintended side effect of Ozempic – and whether we should worry
Yet drugs like Ozempic and Wegovy don't just help people lose fat, but potentially muscle too, new research has suggested.
A study that tested weight loss jabs on mice found that although muscle mass changes less than expected, muscles still get weaker and tissues like the liver also shrink.
Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
The medications, known as semaglutides, predominantly treat diabetes but are also available on the NHS or via private providers to help adults with a high body mass index (BMI).
For example, although Ozempic is used for type 2 diabetes, it is sometimes prescribed off-label as a weight-loss drug.
The results of the study, published in the journal Cell Metabolism, revealed Ozempic-induced weight loss decreased muscle mass by about 10 per cent.
Most of this lost weight wasn't from skeletal muscles, which surround bones and joints, but instead from other tissues like the liver, which shrank by nearly half.
However, because the Ozempic was tested on mice, researchers emphasise that more research is needed to determine whether similar changes to organ size occur in humans and whether those changes come with any risks.
'Loss of mass in metabolically active organs, such as the liver, is expected as part of healthy weight loss,' said Dr Ran Hee Choi, research instructor in nutrition and integrative physiology at the University of Utah college of health, and co-first author on the study.
In both mice and humans, weight gain and loss can affect the size of organs like the liver without affecting their function.
'It's unlikely that the observed lean mass loss represents a serious adverse effect,' added Dr Takuya Karasawa, another co-first author on the study.
Researchers found some skeletal muscles did shrink by about 6 per cent as the mice lost weight, but not enough to explain the overall muscle loss.
However, when someone gains fat, they also tend to gain skeletal muscle. Study authors explain this is because the body needs to work harder to move around.
As a result, losing extra fat can lead to a loss of muscle, which will not affect the person's overall quality of life.
Researchers also tested the amount of force the mice's muscles exerted and found that some muscle strength decreased as the mice lost weight, even when the size of the muscle stayed roughly the same.
This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility.
'The loss of physical function is a strong predictor of not just quality of life but longevity,' added Dr Katsu Funai, professor of nutrition at the University of Utah and the senior author on the study.
Dr Funai concluded that further clinical trials of weight loss jabs should check for changes in muscle strength.
A spokesperson for Novo Nordisk, which makes Ozempic, said: 'In clinical trial for Wegovy or Ozempic we did not specifically study the medicine's impact on muscle mass. In a sub-study of 140 patients with a BMI of 40 or less, analysis suggested that treatment with Wegovy was accompanied by reductions in both fat and lean body mass, with a greater reduction in fat mass than lean body mass.
'We recommend that any patients experiencing side effects while taking Wegovy or Ozempic contact their healthcare provider.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
24 minutes ago
- New York Times
Pill Causes Major Weight Loss in Eli Lilly Trial's Results
People who were overweight or had obesity lost a substantial amount of weight after taking a daily bill made by Eli Lilly, the company reported on Wednesday. The pharmaceutical manufacturer will be applying to the Food and Drug Administration by the end of this year for marketing approval for the medication, which would provide an alternative to injectable drugs that produce weight loss and are already on the market. Eli Lilly plans 'a large investment,' in manufacturing the drug, orforglipron, said Kenneth Custer, executive vice president at Lilly and president of Lilly Cardiometabolic Health The company reported its results in a news release, as drug companies are required to do immediately after they receive study data that could affect their stock price. But the data are not a full report and have not been examined by outside experts. Eli Lilly says it will publish detailed results later this year. The company studied orforglipron in 3,127 adults who were randomly assigned to take one of three doses of the drug or to take a placebo for 72 weeks. It is a GLP-1 drug, like the popular injected weight-loss and diabetes drugs Ozempic and Wegovy, made by Novo Nordisk. Lilly's injected drugs, Mounjaro and Zepbound, have one additional ingredient. Those taking the highest dose of orforglipron lost an average of 27.3 pounds, or 12.4 percent of their body weight. They also reduced their levels of cholesterol, triglycerides, and blood pressure. Like the already approved injected weight-loss drugs, orforglipron's side effects were mostly gastrointestinal — constipation, diarrhea, vomiting and indigestion. In April, Lilly announced results from a similar study of orforglipron in people with type 2 diabetes, reporting that the drug lowered blood sugar and was about as effective as Ozempic in eliciting weight loss in these patients. The company said it would seek F.D.A. approval to market the drug for diabetes in 2026. Orforglipron has not been directly compared with Wegovy or Zepbound. But both of those drugs may give greater weight losses than the pill. In one study comparing those two drugs, people taking Zepbound lost 20.2 percent of their weight and those taking Wegovy lost 13.2 percent over 72 weeks. But, Dr. Custer, noted, the pill has distinct advantages over injected drugs. The injected obesity drugs are sterile solutions that must be kept cold. After the solutions are made they must be put into pens or vials — a 'capital intensive' step, Dr. Custer noted. He said 170 million Americans might benefit from obesity drugs, but just eight million are taking them now. That, he said, is largely a result of 'production limitations.' Pills, in contrast, are easy to make and 'can be manufactured at a significant scale,' Dr. Custer said. 'There are orders of magnitude differences in how many we can support.' And the pills can be used in countries that are unable to supply cold sterile drugs to large numbers of people. Dr. David Cummings, an expert in obesity medicine at the University of Washington, said the ease of manufacturing the pills could be their main advantage. They do not appear to be as effective as injected drugs in helping people lose weight, he noted. But if the pill is marketed at a far lower cost, he said, 'that feature alone could make it truly impactful.' During his confirmation hearing as health secretary, Robert F. Kennedy Jr. called the injectable obesity and diabetes medications 'miracle drugs,' a shift from previous critical remarks he had made about the drugs and their manufacturers. Eli Lilly will not be announcing a price for orforglipron before it is approved for marketing.
Yahoo
an hour ago
- Yahoo
I'm a nutrition expert. Here's what I wish everyone knew about weight loss
Weight loss continues to dominate public discourse – often framed as a matter of personal responsibility. But after nearly 15 years working in and around health and nutrition research, I've seen how weight is treated differently from almost every other health issue. People are routinely blamed for their body size, even though robust evidence shows that weight is shaped by a complex mix of genetics, biology, environment and socioeconomic factors. Limited access to affordable, healthy food, lack of safe places to exercise, long working hours and chronic stress – all more common in disadvantaged areas – can make maintaining a healthy weight significantly harder. Here are five things I wish more people understood about weight loss. 1. It goes against our biology Obesity has been recognised as a national health priority in England since the 1990s, with numerous policies introduced in response. Yet obesity rates have not declined. This suggests that current approaches, which tend to focus on personal responsibility, are not working. Even when weight loss methods are successful, the results often don't last. Research shows that most people who lose weight eventually regain it, and the chances of someone with obesity reaching and maintaining a 'normal' body weight are very low. That's partly because our bodies fight back when we lose weight – a response rooted in our evolutionary past. This process is called metabolic adaptation: when we reduce our energy intake and lose weight, our metabolism slows, and hunger hormones like ghrelin increase, encouraging us to eat more and regain the lost weight. This biological response made sense in our hunter-gatherer past, when feast and famine were common. But today, in a world where high-calorie, ultra-processed food is cheap and accessible, these same survival traits make it easy to gain weight – and difficult to lose it. So if you've struggled to lose weight or keep it off, it's not a personal failure – it's a predictable physiological response. 2. It's not about willpower Some people seem to maintain a stable weight with relative ease, while others struggle. The difference isn't just about willpower. Body weight is influenced by a host of factors. Genetics play a major role – for example, affecting how quickly we burn calories, how hungry we feel, or how full we get after eating. Some people are genetically predisposed to feel hungrier or crave high-energy foods, making weight loss even more challenging. Environmental and social factors also play a part. Having the time, money, or support to prepare healthy meals, be active, and prioritise sleep makes a real difference – and not everyone has those resources. When we overlook these complexities and assume weight is purely a matter of self-control, we contribute to stigma. This stigma can make people feel judged, ashamed, or excluded, which ironically can increase stress, reduce self-esteem, and make healthy habits even harder to adopt. 3. Calories aren't the whole story Counting calories is often the default weight loss strategy. And while creating a calorie deficit is essential for weight loss in theory, in practice, it's far more complicated. For starters, calorie labels on foods are just estimates, and our own energy needs vary from day to day. Even how much energy we absorb from food can differ based on how it's cooked, how it's digested, and the makeup of our gut bacteria. There's also the persistent idea that 'a calorie is just a calorie' – but our bodies don't treat all calories the same. A biscuit and a boiled egg might contain similar calories, but they affect our hunger, digestion, and energy levels very differently. A biscuit may cause a quick blood sugar spike and crash, while an egg provides longer-lasting satiety (fullness) and nutritional value. These misunderstandings have fuelled the rise of fad diets – like only drinking shakes or cutting out entire food groups. While they can lead to short-term weight loss by creating a calorie deficit, they're rarely sustainable and often lack essential nutrients. A more realistic and balanced approach is to focus on long-term changes: eating more whole foods, reducing takeaway meals, cutting back on alcohol and building habits that support overall wellbeing. 4. Exercise is great for your health – but not necessarily for weight loss Many people assume that the more they exercise, the more weight they'll lose. But the science tells a more complex story. Our bodies are very good at conserving energy. After a tough workout, we may unconsciously move less for the rest of the day, or feel hungrier and eat more – offsetting the calories burned. In fact, research shows that total daily energy expenditure doesn't keep rising with more exercise. Instead, the body adjusts by becoming more efficient and reducing energy use elsewhere, making weight loss through exercise alone more difficult than many expect. That said, exercise still offers a huge range of benefits: it boosts cardiovascular health, improves mental wellbeing, maintains muscle mass, enhances metabolic function, strengthens bones and lowers the risk of chronic diseases. Even if the number on the scale doesn't change, exercise is still one of the most powerful tools we have to improve health and quality of life. 5. Health improvements don't always require weight loss You don't have to lose weight to get healthier. While intentional weight loss can reduce the risk of conditions like heart disease and some cancers, studies also show that improving your diet and being more active can significantly improve health markers – like cholesterol, blood pressure, blood sugar and insulin sensitivity – even if your weight stays the same. So if you're not seeing big changes on the scales, it may be more helpful to shift your focus. Instead of chasing a number, focus on behaviour: nourishing your body, moving regularly in ways you enjoy, sleeping well and managing stress. Weight is just one piece of the puzzle – and health is about so much more. Rachel Woods is a Senior Lecturer in Physiology at the University of Lincoln. This article is republished from The Conversation under a Creative Commons license. Read the original article.
Yahoo
an hour ago
- Yahoo
Wegovy, Mounjaro sales in India double on month in July
By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Sales of Danish drugmaker Novo Nordisk's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on Thursday. Demand for the blockbuster anti-obesity drugs, which help control blood sugar and slow digestion, has been on an upswing in the world's most populous nation. Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data showed. Mounjaro sales also doubled month-on-month to 157,000 units or 470 million rupees. "Though Wegovy has a strong prescriber base because of Rybelsus, substantial promotion may be needed to reach the Mounjaro patient base for the injectable market," Pharmarack's Vice President (Commercial) Sheetal Sapale said in a statement. In India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes. Mounjaro's sales have soared 15 times since March, when the drug was launched in India. ($1 = 87.6790 Indian rupees) Sign in to access your portfolio
